INTRODUCTION
MSF is providing cervical cancer screening in Blantyre and Chiradzulu districts in Southern Malawi in the catchment area of 10 health centres. Improved screening strategies under diverse recruitment models are introduced to increase HPV screening coverage at health centres and with outreach activities.
METHODS
Under PAVE study, self-collected vaginal swabs are tested by an isothermal amplification PCR assay followed byvisual inspection, imaging, and histological assessment for HPV +ve women. Women living <5km from health centers are recruited opportunistically during routine visits. After HPV test, they are advised either to wait onsite (test-and-wait model) or called back in two days’ time (test-and-call model) for triage and treatment visit.Women living>10km from health centers are offered HPV test, triage, and treatment in community settings by outreach teams (mobile-clinic model). A fourth model for women living 5-10km from a health center with HPV testing in their communities followed by a triage and treatment visit at respective health centers (mobile-lab model) is not yet implemented.
RESULTS
As of April 2024, over 2000 women have undergone HPV screening across all active sites. Key insights from the experience are focused at: i)streamlining patient flow during opportunistic recruitment at health centers,ii)improving HPV results communication, iii)effectively tracing women back for triage and treatment visits using phone and community based tracing, iv)ensuring provision of stable internet for effective and real time data collection and synchronization, v)reducing gaps in logistics and quality assurances at HPV lab particularly in mobile lab setup, vi)ensuring real-time quality histopathology review of cervical biopsies for case management,and vii)continuous monitoring of patients and data flow to ensure quality of screening, compliance, and effective case management.
CONCLUSIONS
Diverse HPV-based screening strategies are key to achieve good screening coverage, and subsequently reducethe cervical cancer morbidity and mortality in southern Malawi.
Timely and accurate identification of microorganisms and assessment of antimicrobial susceptibility in clinical specimens help clinicians in selecting the most appropriate treatment for their patients. In low-to-middle income countries (LMIC), bacteriological testing is generally not performed routinely due to technological challenges. This contributes to treatment delays and consequent clinical complications, extended hospital stays, and the global spread of multidrug resistance (MDR). The MSF Foundation has developed Antibiogo, an offline smartphone-based application that allows non-microbiologists to carry out antimicrobial susceptibility testing (AST) and interpret the results. We are presenting the preliminary results of the Antibiogo performance evaluation.
METHODS
Antibiogo comprises several components: the Image Analysis Program (IAP) that detects and measures inhibition zone diameters (IZDs); the Expert System (ES) that adjusts AST results based on the application of expert rules and identifies resistance mechanisms; and the Selective Reporting Program. For the evaluation of the IAP, we used collection isolates (n=8) and compared the automatic measurement of IZDs using Antibiogo with the readings made by eight laboratory technicians who inspected the plates manually. For evaluation of the ES, we used Antibiogo to assess 60 pathogens isolated from bone and tissues from patients admitted to MSF’s Reconstructive Surgical Project in Amman, Jordan, between February and September 2020. In parallel, pictures of AST were shared with an external clinical microbiologist who performed an independent and blinded interpretation. Results of the two parallel interpretations were compared and the discordances categorised (minor, major, very major).
RESULTS
Evaluation of the IAP showed good concordance of measurements between technicians and Antibiogo (Krippendorff’s alpha value of 0.957, 95% confidence interval [CI] 0.94-0.97; p<0.001). These results indicate excellent inter-rater agreement between human raters and the Antibiogo platform for these pathogen-antibiotic pairs. For evaluation of the ES, 509 paired samples were read in parallel, and agreement of the measured diameters was excellent (R2=0.95). The ES correctly classified 474 (95.2%) of 498 interpretable samples (95% CI 92.9- 97.4), corresponding to a Krippendorff’s alpha value of 90.6% (95% CI 87%-94%). This indicates excellent to near-perfect agreement. Further investigation of the samples showing non-agreement is underway.
CONCLUSIONS
Preliminary results suggest that Antibiogo is a very promising tool that can be used for the interpretation of antibiograms. This could improve access to microbiology diagnostic tests and the rational use of antibiotics in LMIC. The application currently undergoing further evaluation using a diverse set of pathogens isolated from multiple sites.
ETHICS
This study was approved by the MSF Ethics Review Board and the Hospital Director of Al Mowasah Hospital, Amman, Jordan.